Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)
3.490
+0.030 (0.87%)
Feb 3, 2026, 3:00 PM CST
SHA:600664 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 15,884 | 16,119 | 15,400 | 13,755 | 12,741 | 10,741 |
Other Revenue | 56.83 | 56.83 | 56.21 | 53.63 | 61.06 | 47.59 |
| 15,941 | 16,176 | 15,457 | 13,809 | 12,802 | 10,788 | |
Revenue Growth (YoY) | -1.72% | 4.65% | 11.93% | 7.86% | 18.66% | -8.76% |
Cost of Revenue | 11,751 | 11,655 | 11,443 | 10,446 | 9,826 | 8,543 |
Gross Profit | 4,189 | 4,521 | 4,013 | 3,363 | 2,976 | 2,245 |
Selling, General & Admin | 3,233 | 3,390 | 3,143 | 2,565 | 2,306 | 2,824 |
Research & Development | 149.04 | 136.43 | 106.02 | 115.81 | 97.73 | 92.53 |
Other Operating Expenses | 143.1 | 108.29 | 120.17 | 122.65 | 113.17 | 104.39 |
Operating Expenses | 3,602 | 3,671 | 3,395 | 2,805 | 2,528 | 3,049 |
Operating Income | 587.25 | 849.71 | 618.44 | 557.91 | 447.79 | -803.3 |
Interest Expense | -50.06 | -60.07 | -56.47 | -85.53 | -105.16 | -58.27 |
Interest & Investment Income | 31.37 | 49.47 | 51.58 | 69.19 | 16.5 | 50.42 |
Currency Exchange Gain (Loss) | -5.68 | -5.68 | -5.37 | 3 | 1.99 | -0.83 |
Other Non Operating Income (Expenses) | 70.72 | 66.61 | -22.74 | -19.44 | -5.07 | -176.52 |
EBT Excluding Unusual Items | 633.6 | 900.04 | 585.45 | 525.13 | 356.06 | -988.49 |
Gain (Loss) on Sale of Investments | - | - | - | -20 | - | - |
Gain (Loss) on Sale of Assets | 4.32 | 0.94 | 0.98 | 161.38 | 210.87 | 14.1 |
Asset Writedown | -64.32 | -59.84 | -15.13 | -32.52 | -2.33 | -74.72 |
Other Unusual Items | 71.75 | 33.87 | 79.25 | 67.17 | 65.93 | 80.47 |
Pretax Income | 645.35 | 875.01 | 650.54 | 701.15 | 630.53 | -968.65 |
Income Tax Expense | 160.8 | 184.4 | 176.32 | 188.94 | 220.69 | 76.6 |
Earnings From Continuing Operations | 484.55 | 690.61 | 474.22 | 512.21 | 409.85 | -1,045 |
Minority Interest in Earnings | -35.4 | -61.76 | -78.95 | -47.06 | -38.76 | -32.45 |
Net Income | 449.15 | 628.85 | 395.26 | 465.15 | 371.08 | -1,078 |
Net Income to Common | 449.15 | 628.85 | 395.26 | 465.15 | 371.08 | -1,078 |
Net Income Growth | -26.73% | 59.10% | -15.02% | 25.35% | - | - |
Shares Outstanding (Basic) | 2,505 | 2,515 | 2,470 | 2,448 | 2,474 | 2,506 |
Shares Outstanding (Diluted) | 2,505 | 2,515 | 2,470 | 2,584 | 2,474 | 2,506 |
Shares Change (YoY) | -2.18% | 1.82% | -4.40% | 4.46% | -1.29% | -10.19% |
EPS (Basic) | 0.18 | 0.25 | 0.16 | 0.19 | 0.15 | -0.43 |
EPS (Diluted) | 0.18 | 0.25 | 0.16 | 0.18 | 0.15 | -0.43 |
EPS Growth | -25.10% | 56.25% | -11.11% | 20.00% | - | - |
Free Cash Flow | 172.54 | 691.69 | 863.14 | 532.45 | -239.13 | -846.37 |
Free Cash Flow Per Share | 0.07 | 0.28 | 0.35 | 0.21 | -0.10 | -0.34 |
Gross Margin | 26.28% | 27.95% | 25.96% | 24.35% | 23.24% | 20.81% |
Operating Margin | 3.68% | 5.25% | 4.00% | 4.04% | 3.50% | -7.45% |
Profit Margin | 2.82% | 3.89% | 2.56% | 3.37% | 2.90% | -9.99% |
Free Cash Flow Margin | 1.08% | 4.28% | 5.58% | 3.86% | -1.87% | -7.85% |
EBITDA | 770.89 | 1,066 | 878.27 | 821.32 | 716.99 | -433.54 |
EBITDA Margin | 4.84% | 6.59% | 5.68% | 5.95% | 5.60% | -4.02% |
D&A For EBITDA | 183.64 | 216.29 | 259.83 | 263.41 | 269.2 | 369.75 |
EBIT | 587.25 | 849.71 | 618.44 | 557.91 | 447.79 | -803.3 |
EBIT Margin | 3.68% | 5.25% | 4.00% | 4.04% | 3.50% | -7.45% |
Effective Tax Rate | 24.92% | 21.07% | 27.10% | 26.95% | 35.00% | - |
Revenue as Reported | 15,941 | 16,176 | 15,457 | 13,809 | 12,802 | 10,788 |
Advertising Expenses | - | 1,806 | 1,574 | 1,058 | 340.89 | 201.29 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.